EUVIMEDEUVIMED entdecken
Fallbericht

Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity

Britnee Innocent, Amre A Elmaoued, Kevin Cowart, Raechel T White

American Journal of Health-System Pharmacy · 05.08.2025 · 82 (16) · 886-890

DOI: 10.1093/ajhp/zxaf088 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 12.04.2025. Verfasst von Britnee Innocent und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Taneja College of Pharmacy, Tampa, FL, USA. Hauptthemen laut MEDLINE: Binge-Eating Disorder, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Binge eating disorder (BED) is a psychological disorder that poses several functional consequences for those affected. Management of BED centers around psychological and pharmacological treatment modalities, which have been associated with variable efficacy and the potential for severe adverse effects. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), approved by the Food and Drug Administration for conditions such as diabetes and weight management, are an emerging therapy of interest in BED. Summary In this case report, we describe use of dulaglutide for treatment of a patient with BED, obesity, and type 2 diabetes mellitus. The patient’s baseline binge eating scale (BES) score, glycated hemoglobin level, body mass index (BMI), and weight were obtained. Following these baseline assessments, dulaglutide 0.75 mg once weekly was initiated to optimize management of the patient’s type 2 diabetes. Follow-up measurements were obtained 6 weeks after initiation, at which time reductions in the patient’s BES score, BMI, weight, and BED symptoms were observed. Moreover, dulaglutide was well tolerated without adverse drug events.

Conclusion

This case report describes the use of dulaglutide in the management of mild BED in the setting of comorbid type 2 diabetes and obesity. Further research is necessary to evaluate the long-term effectiveness of GLP-1 RAs in the management of BED and to determine the optimal duration and dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Binge-Eating DisorderDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsObesityRecombinant Fusion ProteinsHumans

Stichwörter der Autor:innen

binge eating disorderdulaglutideglucagon-like peptide-1incretin therapy

Substanzen

dulaglutideGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • University of South Florida Taneja College of Pharmacy, Tampa, FL, USA.
  • University of New Mexico College of Pharmacy, Albuquerque, NM, USA.

Zitieren

APA

Innocent, B., Elmaoued, A. A., Cowart, K., & White, R. T. (2025). Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity. American Journal of Health-System Pharmacy, 82(16), 886-890. https://doi.org/10.1093/ajhp/zxaf088

Vancouver

Innocent B, Elmaoued AA, Cowart K, White RT. Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity. American Journal of Health-System Pharmacy. 2025;82(16):886-890. doi:10.1093/ajhp/zxaf088

BibTeX
@article{Innocent2025,
  author = {Innocent, Britnee and Elmaoued, Amre A and Cowart, Kevin and White, Raechel T},
  title = {Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  volume = {82},
  number = {16},
  pages = {886--890},
  doi = {10.1093/ajhp/zxaf088}
}
Kostenlos starten →